Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 1, 1998, Pages 194-196

  Roblin, Patricia M ^a   Hammerschlag, Margaret R ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; ERYTHROMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIUM ISOLATION; CHILD; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PERSISTENT INFECTION; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0031962016     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.1.194     Document Type: Article

References (13)

1. Anderson, G., T. S. Esmonde, S. Coles, J. Macklin, and C. Carnegie. 1991. A comparative study of clarithromycin and erythromycin stearate in community acquired pneumonia. J. Antimicrob. Chemother. 27(Suppl. A):117-124.
2. Block, S., J. Hedrick, M. R. Hammerschlag, G. H. Cassell, and C. Craft. 1995. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs erythromycin ethylsuccinate. Pediatr. Infect. Dis. J. 14:471-477.
3. Chien, S. M., P. Pichotta, N. Stepman, and C. K. Chan. 1993. Treatment of community-acquired pneumonia. A multicenter, double blind, randomized study comparing clarithromycin to erythromycin. Chest 103:697-701.
4. Grayston, J. T., L. A. Campbell, C.-C. Kuo, C. H. Mordhorst, P. Saikku, D. H. Thom, and S. P. Wang. 1990. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J. Infect. Dis. 161:618-625.
5. Hammerschlag, M. R., K. Chirgwin, P. M. Roblin, M. Gelling, W. Dumornay, L. Mandel, P. Smith, and J. Schachter. 1992. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin. Infect. Dis. 14:178-182.
6. Hammerschlag, M. R., K. K. Qumei, and P. M. Roblin. 1992. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob. Agents. Chemother. 36:1573-1574.
7. Jones, R. B., B. Van Der Pol, D. H. Martin, and M. K. Shepard. 1990. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J. Infect. Dis. 162:1309-1315.
8. Mourad, A., R. L. Sweet, N. Sugg, and J. Schachter. 1980. Relative resistance to erythromycin in Chlamydia trachomatis. Antimicrob. Agents Chemother. 18:696-698.
9. Roblin, P. M., W. Dumornay, and M. R. Hammerschlag. 1992. Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae. J. Clin. Microbiol. 30:1968-1971.
10. Roblin, P. M., G. Montalban, and M. R. Hammerschlag. 1994. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob. Agents Chemother. 38:1588-1589.
11. Roord, J. J., B. H. M. Wolf, M. M. H. T. Goossens, and J. L. L. Kimpen. 1996. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. Antimicrob. Agents Chemother. 40:2765-2768.
12. Schoenwald, S., V. Skerk, I. Petricevec, V. Car, L. Majerus-Misic, and M. Gunjaca. 1991. Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 10:877-880.
13. Schonwald, S., B. Barsic, I. Klinar, and M. Gunjaca. 1994. Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. Scand. J. Infect. Dis. 26:706-710.